Stockreport

Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes

Incannex Healthcare Inc.  (IXHL) 
PDF MELBOURNE, Australia and NEW YORK, March 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing in [Read more]